Cover Image
市場調查報告書

ADHD醫藥品思銳(Strattera)的長期預測模式

BCC Research Strattera Forecast: Long Term Forecasting Model for ADHD Drug Strattera

出版商 BCC Research 商品編碼 307101
出版日期 內容資訊 英文 Excel file/database
訂單完成後即時交付
價格
Back to Top
ADHD醫藥品思銳(Strattera)的長期預測模式 BCC Research Strattera Forecast: Long Term Forecasting Model for ADHD Drug Strattera
出版日期: 2014年07月01日 內容資訊: 英文 Excel file/database
簡介

思銳(Strattera)是Eli Lilly and Company公司銷售的醫藥品,使用於注意力不足過動症障礙(ADHD:Attention Deficit Hyperactivity Disorder)的治療。思銳從2016年末到2017年其品牌專利保護的效力將喪失,將開放給競爭企業的非專利治療藥銷售市場。

本報告以ADHD治療藥思銳市場為主題,提供考慮進入這個產品領域的企業可利用於決策的,從2016年到2030年的需求預測(患者數及銷售額規模),各主要國家市場預測等定量性的市場預測資料之Excel形式的資料庫。

  • 圖1:摘要圖表-美金金額及患者數,各地區,2010-2030年
  • 表格1:整個市場的圖表-各區域銷售額及患者數,2016-2030年
  • 表格2:美國的患者數,2010-2030年
  • 表格3:日本的患者數,2010-2030年
  • 表格4:法國的患者數,2010-2030年
  • 表格5:德國的患者數,2010-2030年
  • 表格6:義大利的患者數,2010-2030年
  • 表格7:西班牙的患者數,2010-2030年
  • 表格8:英國的患者數,2010-2030年
  • 表格9:美國的估計人口,性別、各年齡,2015-2060年
  • 表格10:歐洲推算人口,2010-2030年
  • 表格11:日本推算人口,2010-2030年
  • 表格12:美國的價格設定及外匯比率,思銳年度成本,2010-2030年
  • 表格13:日本的價格設定及外匯比率,思銳年度成本,2010-2030年
  • 表格14:法國的價格設定及外匯比率,思銳年度成本,2010-2030年
  • 表格15:德國的價格設定及外匯比率,思銳年度成本,2010-2030年
  • 表格16:西班牙的價格設定及外匯比率,思銳年度成本,2010-2030年
  • 表格17:英國的價格設定及外匯比率,思銳年度成本,2010-2030年
目錄
Product Code: FMO002A

BCC Research is pleased to announce the BCC Research Strattera® Forecast , a strategic investment product designed to provide market data for the pharmaceutical drug Strattera®, a treatment for Attention Deficit Hyperactivity Disorder (ADHD) distributed by Eli Lilly and Company. Strattera® will lose its branded patent protection in late 2016 going into 2017, opening the market to distribution of generic treatments by competing companies.

With BCC Research's Strattera® Forecast, you will have quantitative data about forecasted revenue for the pharmaceutical drug Strattera® that will guide you in your strategic decision-making regarding future participation in this product sector.

The BCC Research Strattera® Forecast is a quantitative forecast model in an easily accessible Microsoft® Excel® spreadsheet, featuring:

Market demand forecasts for Strattera® annually for the years 2016 to 2030 by volume (number of patients) and value (in U.S. dollars)

Segmentation of volume and value for these regions:

  • United States
  • Japan
  • France
  • Germany
  • Italy
  • Spain
  • United Kingdom

Interactive data for:

  • Patient volumes, with forecasts by age range and prevalence, as well as population estimates
  • Product pricing forecasts

Use the BCC Research Strattera® Forecast to:

  • Examine forecasted market demand for Strattera®
  • Validate other Strattera® market-demand data to which you have access
  • Make strategic decisions about entering Strattera®-related or Attention Deficit Hyperactivity Disorder (ADHD) treatment-related markets

Table of Contents

  • Figure 1- Summary graphs-Value in USD and Patient Volumes, by Region, 2010-2030
  • Table 1-Total market graphs-Revenue by Region and Patient Volumes, 2016 to 2030
  • Table 2-US Patient Volumes, 2010 to 2030
  • Table 3-Japan Patient Volumes, 2010 to 2030
  • Table 4-France Patient Volumes, 2010 to 2030
  • Table 5-German Patient Volumes, 2010 to 2030
  • Table 6-Italy Patient Volumes, 2010 to 2030
  • Table 7-Spain Patient Volumes, 2010 to 2030
  • Table 8-UK Patient Volumes, 2010 to 2030
  • Table 9-US Population Estimates, Sex and Age, 2015 to 2060
  • Table 10-Europe Population Estimates, 2010 to 2030
  • Table 11-Japan Population Estimates, 2010 to 2030
  • Table 12-US Pricing and FX Rates, Strattera Annual Costs, 2010 to 2030
  • Table 13-Japan Pricing and FX Rates, Strattera Annual Costs, 2010 to 2030
  • Table 14-France Pricing and FX Rates, Strattera Annual Costs, 2010 to 2030
  • Table 15-German Pricing and FX Rates, Strattera Annual Costs, 2010 to 2030
  • Table 16-Spain Pricing and FX Rates, Strattera Annual Costs, 2010 to 2030
  • Table 17-UK Pricing and FX Rates, Strattera Annual Costs, 2010 to 2030
Back to Top